Arcutis Biotherapeutics Inc (NASDAQ:ARQT) — Market Cap & Net Worth
Market Cap & Net Worth: Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) has a market capitalization of $2.90 Billion ($2.90 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5045 globally and #1603 in its home market, demonstrating a 2.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arcutis Biotherapeutics Inc's stock price $23.35 by its total outstanding shares 124033382 (124.03 Million). Analyse Arcutis Biotherapeutics Inc (ARQT) cash conversion ratio to see how efficiently the company converts income to cash.
Arcutis Biotherapeutics Inc Market Cap History: 2020 to 2026
Arcutis Biotherapeutics Inc's market capitalization history from 2020 to 2026. Data shows growth from $3.49 Billion to $2.90 Billion (1.10% CAGR).
Index Memberships
Arcutis Biotherapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.12% | #120 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.01% | #550 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.17% | #76 of 263 |
Weight: Arcutis Biotherapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Arcutis Biotherapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arcutis Biotherapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.58x
Arcutis Biotherapeutics Inc's market cap is 9.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.84 Billion | $3.69 Million | -$311.46 Million | 498.02x | N/A |
| 2023 | $400.63 Million | $59.61 Million | -$262.14 Million | 6.72x | N/A |
| 2024 | $1.73 Billion | $196.54 Million | -$140.04 Million | 8.79x | N/A |
| 2025 | $3.60 Billion | $376.07 Million | -$16.14 Million | 9.58x | N/A |
Competitor Companies of ARQT by Market Capitalization
Companies near Arcutis Biotherapeutics Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Arcutis Biotherapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Arcutis Biotherapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Arcutis Biotherapeutics Inc's market cap moved from $3.49 Billion to $ 2.90 Billion, with a yearly change of 1.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.90 Billion | -19.59% |
| 2025 | $3.60 Billion | +108.47% |
| 2024 | $1.73 Billion | +331.27% |
| 2023 | $400.63 Million | -78.18% |
| 2022 | $1.84 Billion | -28.64% |
| 2021 | $2.57 Billion | -26.27% |
| 2020 | $3.49 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Arcutis Biotherapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.90 Billion USD |
| MoneyControl | $2.90 Billion USD |
| MarketWatch | $2.90 Billion USD |
| marketcap.company | $2.90 Billion USD |
| Reuters | $2.90 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a po… Read more